Overview

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Manhattan Eye, Ear & Throat Hospital
Collaborators:
Alcon Research
LuEsther T. Mertz Retinal Research Center
Treatments:
Anecortave
Hydrocortisone